Summary: A decade-long investigation indicates that naturally occurring lithium in the brain helps protect against Alzheimer’s disease by preserving normal function across major brain cell types. Researchers report that lithium loss is among the earliest measurable brain changes associated with Alzheimer’s and often precedes clear symptoms.
In mouse models, lowering brain lithium produced core features of Alzheimer’s, while restoring lithium with an amyloid-evading form, lithium orotate, reversed cognitive deficits. These results suggest a new direction for early detection, prevention, and treatment that targets a fundamental contributor to neurodegeneration instead of only isolated disease markers.
Key Facts
- Early Indicator: Brain lithium levels decline at the earliest stages of Alzheimer’s.
- Driver of Pathology: Lithium loss promotes amyloid accumulation, inflammation, and neuronal damage.
- Therapeutic Promise: Low-dose lithium orotate restored memory and reversed pathology in mouse studies.
Source: Harvard
What triggers the slow erosion of memory in Alzheimer’s disease, and why do some people with Alzheimer’s-like brain changes remain cognitively intact?
These long-standing questions have challenged neuroscientists for decades. New research from Harvard Medical School points to a surprising candidate: an everyday trace element, lithium, naturally present in the brain.
Published in Nature, the study demonstrates for the first time that measurable levels of endogenous lithium exist in the human brain, that lithium supports overall brain health, and that its loss contributes to neurodegeneration by affecting multiple brain cell types.
Based on a decade of work combining mouse experiments with analysis of human brain tissue and blood samples across stages of cognitive health, the researchers found that lithium depletion is an early event in Alzheimer’s. In mice, similar lithium loss accelerated pathological hallmarks and memory decline. The team also showed that amyloid plaques bind lithium and reduce its availability, and that a lithium compound designed to avoid amyloid binding — lithium orotate — can restore memory in mice.
These findings help reconcile prior observations in patients and offer a unified theory of disease progression: rather than seeing amyloid, tau, or other markers in isolation, lithium homeostasis may be a central factor that determines whether those markers lead to clinical dementia.
Alzheimer’s affects millions worldwide and involves diverse brain abnormalities — amyloid-beta deposits, tau tangles, loss of protective proteins like REST, and inflammatory changes — yet none of these alone fully explains who develops dementia. Population studies have hinted that higher environmental lithium, including in drinking water, correlates with lower dementia rates. This new work goes further by directly measuring lithium in human brains and demonstrating a functional role.
“The idea that lithium deficiency could be a cause of Alzheimer’s disease is new and suggests a different therapeutic approach,” said senior author Bruce Yankner, professor of genetics and neurology at Harvard Medical School, who previously helped establish amyloid beta’s toxicity. He and colleagues suggest that restoring physiological lithium levels could address multiple aspects of Alzheimer’s rather than targeting a single pathological signature.
Lithium depletion is an early sign of Alzheimer’s
Yankner’s group investigated whether lithium exists naturally in the human brain and whether its levels change during neurodegeneration. Working with the Rush Memory and Aging Project, which maintains a large bank of donated postmortem brain tissue spanning the full range of cognitive states, the team used advanced mass spectrometry to measure trace metals in brain and blood.
Of approximately 30 metals analyzed, lithium was the only one showing a marked decline early in the disease process. Lithium levels were robust in cognitively healthy donors but were substantially reduced in individuals with mild cognitive impairment and further diminished in those with full Alzheimer’s. The finding was replicated across several brain banks, establishing a baseline range of natural brain lithium in people who had not received lithium treatments.
This pattern supports the idea that lithium behaves like a trace nutrient — present at biologically meaningful concentrations that contribute to brain resilience during aging. It also suggests lithium measurement could become part of early screening approaches if validated clinically.
Loss of lithium causes Alzheimer’s-related changes
To test causality, the researchers reduced dietary lithium in healthy mice until brain lithium matched levels observed in Alzheimer’s patients. Lithium depletion produced accelerated brain aging: increased inflammation, loss of synapses, axons, and myelin, and measurable cognitive decline.
In established Alzheimer’s mouse models, low lithium dramatically increased amyloid-beta deposition and phospho-tau accumulation. Microglia became pro-inflammatory and less effective at clearing amyloid. Gene activity shifted in ways that overlap with human Alzheimer’s risk pathways, including effects on the APOE network and activation of the kinase GSK3β.
Restoring lithium through low-dose lithium orotate reversed pathological changes and recovered memory even in older mice with advanced disease. Maintaining stable lithium earlier in life prevented disease onset in these models, supporting a causal role for lithium deficiency in driving Alzheimer’s pathology.
A promising avenue for treatment and prevention
Previous clinical trials of conventional lithium salts used for psychiatric disorders have been limited by toxicity at standard doses for older adults. The new work explains one reason: amyloid sequesters those lithium compounds before they can exert protective effects. Using a screening platform, the authors identified lithium orotate as a salt with reduced amyloid binding and potent effects at very low, physiologic doses — roughly one-thousandth of psychiatric doses — with no evidence of toxicity in long-treated mice.
If replicated in human trials, routine blood tests to monitor lithium and targeted treatment with amyloid-evading lithium salts could become strategies to identify at-risk individuals and prevent or delay disease onset. The authors caution that lithium therapies must be evaluated in controlled clinical trials and that people should not self-administer lithium supplements without medical supervision.
“My hope is that lithium will do something more fundamental than anti-amyloid or anti-tau therapies — not just slowing decline but reversing cognitive loss and improving patients’ lives,” Yankner said.
Funding: This research was supported by the National Institutes of Health (grants R01AG046174, R01AG069042, K01AG051791, DP2AG072437, P30AG10161, P30AG72975, R01AG15819, R01AG17917, U01AG46152, and U01AG61356), the Ludwig Family Foundation, the Glenn Foundation for Medical Research, and the Aging Mind Foundation.
About this Alzheimer’s disease and neurology research news
Author: Stephanie Dutchen
Source: Harvard
Contact: Stephanie Dutchen – Harvard
Image: The image is credited to Neuroscience News
Original Research: Open access. “Lithium deficiency and the onset of Alzheimer’s disease” by Bruce Yankner et al., Nature.
Abstract
Lithium deficiency and the onset of Alzheimer’s disease
The earliest molecular changes in Alzheimer’s disease (AD) are incompletely understood. This study shows that endogenous lithium is dynamically regulated in the brain and supports cognitive preservation during aging.
Among the metals analyzed, lithium was uniquely reduced in the brains of people with mild cognitive impairment, and its bioavailability was further lowered in AD through sequestration by amyloid. Dietary depletion of endogenous lithium in wild-type and AD mouse models produced a roughly 50% cortical lithium reduction that markedly increased amyloid-β deposition, phospho-tau accumulation, pro-inflammatory microglial activation, and loss of synapses, axons, and myelin, accelerating cognitive decline via pathways that include activation of GSK3β.
Single-nucleus RNA sequencing revealed that lithium deficiency induces transcriptomic changes across multiple brain cell types that overlap with Alzheimer’s signatures. Replacement therapy with lithium orotate, a salt with reduced amyloid binding, prevented pathological changes and memory loss in AD models and aging wild-type mice. These findings reveal physiological roles for endogenous lithium in the brain and indicate that disruption of lithium homeostasis may be an early event in AD pathogenesis. Amyloid-evading lithium salts merit further study as potential preventive and therapeutic approaches.